VJToday /Features

EV-302/KEYNOTE-A39: combination enfortumab vedotin and pembrolizumab improves outcomes versus chemotherapy in patients with advanced urothelial carcinoma

The Phase III EV-302/KEYNOTE-A39 (NCT04223856) trial demonstrated that the combination of enfortumab vedotin and pembrolizumab significantly improved overall survival (OS)…

VJToday
1 week

SIENDO: long-term PFS findings of maintenance selinexor in TP53wt endometrial cancer

Endometrial cancer is the most common gynecological cancer, where approximately 417,000 cases and 100,000 deaths were reported worldwide in 2020.1…

VJToday
3 months

BWEL: a phone-based weight loss intervention in early-stage breast cancer

Initial data from the Phase III Breast Cancer Weight Loss Study (BWEL) (NCT02750826) has shown promising results for a telephone-based…

Breast Cancer VJToday
4 months

SPOTLIGHT: zolbetuximab plus chemotherapy prolongs PFS and OS in CLDN18.2+ metastatic gastric cancer

Primary results from the Phase III SPOTLIGHT (NCT03504397) trial demonstrated a significant survival benefit for patients with Claudin18.2 (CLDN18.2)-positive, HER2-negative,…

VJToday
8 months

Managing urothelial carcinoma with targeted therapies 

VJOncology is excited to present the latest data and developments in the bladder cancer field, with comments from Yohann Loriot, Jonathan…

VJToday
9 months

FDA approves atezolizumab for unresectable or metastatic alveolar soft part sarcoma

On December 9th 2022, The US Food and Drug Administration (FDA) permitted the approval of atezolizumab for adult and pediatric…

VJToday
10 months

Trastuzumab deruxtecan and the evolving HER2-low breast cancer landscape 

VJOncology is excited to present the latest data and developments in the HER2-low breast cancer field, with comments from experts…

VJToday
10 months

FDA approves combination therapy of tremelimumab, durvalumab, and platinum-based chemotherapy for metastatic NSCLC

The U.S. Food and Drug Administration (FDA) have approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small…

VJToday
10 months

EMERALD: updated results on the impact of duration of prior CDK4/6i  and FDA priority review

The U.S. Food and Drug Administration (FDA) has granted priority review for elacestrant, a selective estrogen receptor degrader (SERD), based…

VJToday
11 months

Worse outcomes for immunosuppressed patients with cancer and COVID-19 treated with immunotherapy

A report published in JAMA Oncology suggests that cancer patients with baseline immunosuppression and COVID-19 experience worse outcomes and an…

VJToday
11 months
The content of VJOncology is intended for healthcare professionals